Introduction
Cooperation between China and Germany in healthcare has grown steadily over several decades, evolving from early academic exchanges into comprehensive partnerships that span public health, biomedical research, and pharmaceutical collaboration. Today, this bilateral relationship stands as one of the most dynamic examples of East-West medical integration, bringing together the strengths of modern German pharmaceutical science and the centuries-old traditions of Chinese medicine.
A Growing Bilateral Healthcare Partnership
In recent years, enterprises and institutions from both countries have engaged in increasingly frequent exchanges, fostering meaningful dialogue, strengthening mutual trust, and reaching a range of cooperation agreements. These engagements reflect a shared commitment to advancing global healthcare standards and creating channels for the exchange of medical knowledge, products, and expertise between the two nations.
The 2025 Sino-Germany Pharmaceutical Conference
In November 2025, the 3rd Sino-Germany Cross-Border Pharmaceutical and Health Industry Cooperation and Exchange Conference was held at the Daxing Biomedicine Industrial Base in Beijing. The event highlighted cutting-edge fields such as natural medicines, probiotics, and organic skincare, featuring keynote speeches, product exhibitions, and structured networking sessions designed to build an efficient and practical platform for communication between Chinese and German enterprises.
“The exhibition brings together innovative products from both Germany and China, including advanced AI-powered medical devices,” said Ao Miaomiao, General Manager of HCP GmbH, one of the conference co-organizers. She expressed hope that Germany will continue deepening its engagement in the Chinese market, promoting pharmacist-developed products while helping high-quality Chinese products expand into the European market. HCP GmbH is a pioneering German pharmaceutical and healthcare enterprise that has been actively building its presence in China, helping bridge regulatory and commercial gaps between the two markets.
German Market Embraces Traditional Chinese Medicine
Not only are German pharmaceutical products well received in China, but Traditional Chinese Medicine (TCM) is also gaining remarkable popularity in Germany. Last year, a traditional Chinese herbal beverage produced by Anhui Jiren Pharmaceutical became available not only in local German pharmacies but also on the menus of cafes in Hamburg, where it is served as a daily wellness supplement.
“From treatment to wellness, we seek to integrate TCM’s health-preserving culture into the daily lives of Europeans,” said Zhu Qiang, Deputy General Manager of Anhui Jiren Pharmaceutical. This shift reflects a broader consumer trend in Europe toward preventive healthcare and holistic wellness approaches rooted in traditional medicine systems.
TCM Granules Gaining European Acceptance
Anhui Jiren Pharmaceutical entered the European market in 2018, and since then, 193 of its TCM granule varieties have passed official German quality inspections and are now commercially available across the European market. The company continues to explore new strategies for global expansion, including forging stronger ties with overseas research institutions to validate TCM’s efficacy with rigorous scientific evidence.
“We are exploring new approaches to bring more products to the global market, including strengthening ties with overseas research institutions to prove TCM’s efficacy with scientific evidence,” Zhu Qiang added. This science-backed approach is essential for gaining broader regulatory acceptance and consumer confidence in Western markets.
Academic Institutions Building Research Bridges
In December 2025, Li Kun, Vice President of the China Academy of Chinese Medical Sciences, led a delegation on an academic visit to Germany, resulting in multiple cooperation agreements with leading German research institutions. Among these were Charité, one of Europe’s most prestigious university hospitals, and the University Medical Center Hamburg-Eppendorf. Both parties signed a Memorandum of Understanding (MoU) outlining their intent to foster deeper exchange between Chinese and Western medicines and establish long-term scientific research partnerships.
These academic linkages are pivotal in legitimizing TCM within the global medical community, enabling collaborative clinical studies and evidence-based research that can support the wider adoption of Chinese medicine practices in Europe and beyond.
Hong Kong–Germany TCM Collaboration Agreement
In January 2025, the Chinese Medicine Hospital of Hong Kong (CMHHK) and TCM-Klinik Bad Kötzting (TCM-KBK) in Germany signed a strategic collaboration agreement. Under the agreement, both institutions committed to exchanging Chinese medicine professionals, promoting the clinical integration of Chinese and Western medicine, and establishing a cross-border scientific research network dedicated to advancing the field of Chinese medicine globally.
This partnership represents one of the most structured bilateral efforts yet, combining clinical practice, talent development, and academic research under a single cooperative framework.
Conclusion
The deepening healthcare cooperation between China and Germany signals a transformative moment in global medicine. From pharmaceutical conferences and herbal beverages in German cafes to formal MoUs between top research hospitals, the collaboration is multidimensional and growing. As both countries invest in bridging Eastern and Western medical traditions, the world stands to benefit from a richer, more integrated approach to health and wellness.
